Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

January 13, 2022

Study Completion Date

January 13, 2022

Conditions

Cognitive Impairment, MildAlzheimer Disease

Interventions

DRUG

Rapamune

Sirolimus 1mg capsules

Trial Locations (1)

UTHSA McDermott Clinical Sciences Building, San Antonio

All Listed Sponsors

collaborator

National Center for Advancing Translational Sciences (NCATS)

NIH

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT04200911 - Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway | Biotech Hunter | Biotech Hunter